Hyloris Pharmaceuticals 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Stijn Van Rompay

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	34.9%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	데이터 없음

최근 관리 업데이트

Recent updates

CEO

Stijn Van Rompay

no data

테뉴어

Mr. Stijn Van Rompay is a Co-Founder, Chief Executive Officer and Director Hyloris Pharmaceuticals SA. He was the Chief Executive Officer of Alter Pharma, a high-growth pharmaceutical company focused on th...

Hyloris Pharmaceuticals 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Hyloris Pharmaceuticals SA, Annual General Meeting, Jun 04, 2024

Hyloris Pharmaceuticals SA, Annual General Meeting, Jun 08, 2021

Hyloris Pharmaceuticals SA Appoints Dietmar Aichhorn as Chief Operating Officer

Recent updates

Hyloris Pharmaceuticals SA to Report Fiscal Year 2024 Results on Mar 20, 2025

Hyloris Pharmaceuticals SA to Report Fiscal Year 2024 Final Results on Apr 30, 2025

Hyloris Pharmaceuticals SA to Report First Half, 2024 Results on Sep 05, 2024

Hyloris Pharmaceuticals SA Enrolls First Patient in Phase 3 Clinical Trial for Its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures

Hyloris Pharmaceuticals SA Announces Positive Results for the Phase 2 Trial of Miconazole Domiphen-Bromide (MCZ-DB) in Patients with Acute Vulvovaginal Candidiasis

Hyloris Pharmaceuticals SA Announces U.S. FDA Approval of Maxigesic® IV

Hyloris Pharmaceuticals SA, Annual General Meeting, Jun 04, 2024

Hyloris Pharmaceuticals SA Expands Its Pipeline with A Product Candidate for A Mineral Deficiency in the Blood (Hypophosphatemia)

Hyloris Pharmaceuticals SA Broadens Pipeline with A Nasal Product Candidate for Idiopathic Rhinitis

Hyloris Pharmaceuticals SA to Report Fiscal Year 2022 Results on Apr 28, 2023

Hyloris Pharmaceuticals SA to Report Fiscal Year 2022 Results on Mar 16, 2023

Hyloris Reports Positive Phase 1 Data for HY-004, A Proprietary Tranexamic Acid Oral Mouth Rinse for Bleeding Related to Dental Procedures

Hyloris Pharmaceuticals SA Receives Complete Response Letter from the US Food and Drug Administration on its Application for the US Registration of Maxigesic IV

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Forecast to breakeven in 2024

Hyloris Pharmaceuticals SA Announces Further Extension of Maxigesic® Iv Footprint

First half 2021 earnings released: €0.32 loss per share (vs €0.21 loss in 1H 2020)

Forecast to breakeven in 2024

Full year 2020 earnings released: €0.33 loss per share (vs €0.37 loss in FY 2019)

Revenue misses expectations

Hyloris Pharmaceuticals SA, Annual General Meeting, Jun 08, 2021

Hyloris Pharmaceuticals SA to Report First Half, 2021 Results on Aug 04, 2021

Hyloris and Purna Female Healthcare Announce Partnership to Develop Novel Women’s Health Product

New 90-day high: €10.16

Hyloris Pharmaceuticals SA Appoints Dietmar Aichhorn as Chief Operating Officer

First half earnings released

CEO

테뉴어